GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » Shares Outstanding (EOP)

KYTHERA Biopharmaceuticals (FRA:KYT) Shares Outstanding (EOP) : 26.25 Mil (As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. KYTHERA Biopharmaceuticals's shares outstanding for the quarter that ended in Jun. 2015 was 26.25 Mil.

KYTHERA Biopharmaceuticals's quarterly shares outstanding increased from Mar. 2015 (25.80 Mil) to Jun. 2015 (26.25 Mil). It means KYTHERA Biopharmaceuticals issued new shares from Mar. 2015 to Jun. 2015 .

KYTHERA Biopharmaceuticals's annual shares outstanding increased from Dec. 2013 (21.75 Mil) to Dec. 2014 (22.69 Mil). It means KYTHERA Biopharmaceuticals issued new shares from Dec. 2013 to Dec. 2014 .


KYTHERA Biopharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for KYTHERA Biopharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KYTHERA Biopharmaceuticals Shares Outstanding (EOP) Chart

KYTHERA Biopharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14
Shares Outstanding (EOP)
1.38 1.40 18.33 21.75 22.69

KYTHERA Biopharmaceuticals Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.67 22.68 22.69 25.80 26.25

Competitive Comparison of KYTHERA Biopharmaceuticals's Shares Outstanding (EOP)

For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KYTHERA Biopharmaceuticals's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where KYTHERA Biopharmaceuticals's Shares Outstanding (EOP) falls into.



KYTHERA Biopharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


KYTHERA Biopharmaceuticals  (FRA:KYT) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


KYTHERA Biopharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Traded in Other Exchanges
N/A
Address
KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines